Trial Profile
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms HR-pQCT study
- 01 Jan 2023 Results of a preplanned analyses from parent and extension studies (NCT01440803 and NCT02049866) of high-resolution peripheral quantitative computed tomography scans assessing effects on volumetric BMD, microarchitecture, and estimated strength at distal radius and tibia published in the Journal of Bone and Mineral Research
- 15 Nov 2022 Status changed from active, no longer recruiting to completed.
- 16 Apr 2022 Results from NCT01440803 and NCT02049866 , defining effects of treatment with teriparatide followed by denosumab on Lumbar Spine (LS) volumetric BMD (vBMD) and stiffness by finite element analysis assessed on central QCT scan, published in the Journal of Clinical Endocrinology and Metabolism